脑安胶囊联合艾地苯醌治疗急性脑梗死的临床研究  

Clinical study on Naoan Capsules combined with idebenone in treatment of acute cerebral infarction

作　　者：李艳明 张紫萱 肖理红 肖瑾 胡金花 林冬 罗佳 LI Yan-ming;ZHANG Zi-xuan;XIAO Li-hong;XIAO Jin;HU Jin-hua;LIN Dong;LUO Jia(Department of Neurology,the Affiliated Hospital of Xiangtan Medicine&Health Vocational College(the Third People’s Hospital of Xiangtan),Xiangtan 411102,China;Department of Neurology,Xiangtan Central Hospital,Xiangtan 411100,China;Xiangtan Medicine&Health Vocational College,Xiangtan 411104,China)

机构地区：[1]湘潭医卫职院附属医院(湘潭市第三人民医院)神经内科,湖南湘潭411102 [2]湘潭市中心医院神经内科,湖南湘潭411100 [3]湘潭医卫职业技术学院,湖南湘潭411104

出　　处：《现代药物与临床》2022年第12期2750-2754,共5页Drugs & Clinic

基　　金：湖南省卫生健康委2020年度科研立项课题(20201196)。

摘　　要：目的 探讨脑安胶囊联合艾地苯醌片治疗急性脑梗死的临床疗效。方法 选取2020年1月—2021年12月湘潭医卫职院附属医院(湘潭市第三人民医院)收治的80例急性脑梗死患者,根据随机数字表法将80例患者随机分为对照组和治疗组,每组各40例。对照组患者口服艾地苯醌片,30 mg/次,3次/d。治疗组患者在对照组治疗的基础上口服脑安胶囊,0.8g/次,2次/d。两组患者连续治疗4周。观察两组的临床疗效,比较两组的功能综合评定量表(FCA)评分、美国国立卫生研究院脑卒中量表(NIHSS)评分、低灌注区面积以及血清抗心磷脂抗体(ACA)、趋化因子配体12(CXCL12)、基质金属蛋白酶8(MMP-8)水平。结果 与对照组(75.00%)相比,治疗组的总有效率(92.50%)更高,差异有统计学意义(P<0.05)。治疗后,两组的FCA评分显著增大,NIHSS评分显著减小(P<0.05);治疗组的FCA评分高于对照组,NIHSS评分低于对照组,差异有统计学意义(P<0.05)。治疗后,两组的低灌注区面积均显著缩小(P<0.05),治疗组的低灌注区面积明显小于对照组,差异有统计学意义(P<0.05)。治疗后,两组的血清ACA、CXCL12、MMP-8水平均明显降低(P<0.05);治疗组的血清ACA、CXCL12、MMP-8水平均低于对照组(P<0.05)。结论 脑安胶囊联合艾地苯醌片治疗急性脑梗死的疗效确切,可改善神经功能,缩小低灌注区面积,降低血管内皮损伤,且药物安全性良好。Objective To investigate the clinical efficacy of Naoan Capsules combined with Idebenone Tablets in treatment of acute cerebral infarction. Methods Patients(80 cases) with acute cerebral infarction in the Affiliated Hospital of Xiangtan Medicine &Health Vocational College(the Third People’s Hospital of Xiangtan) from January 2020 to December 2021 were divided into control and treatment groups according to random number table method, and each group had 40 cases. Patients in the control group were po administered with Idebenone Tablets, 30 mg/time, three times daily. Patients in the treatment group were po administered with Naoan Capsules on the basis of the control group, 0.8 g/time, twice daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and FCA scores, NIHSS scores, the area of low perfusion area, the levels of ACA, CXCL12, and MMP-8 in two groups were compared. Results Compared with the control group(75.00%), the total effective rate of the treatment group(92.50%) was higher, and the difference was statistically significant(P < 0.05). After treatment, the FCA score in two groups were significantly increased, but the NIHSS score in two groups significantly were decreased(P < 0.05). The FCA score of the treatment group was higher than that of the control group, but the NIHSS score of the treatment group was lower than that of the control group,and the difference was statistically significant(P < 0.05). After treatment, the area of low perfusion area in two groups significantly were decreased(P < 0.05), and the area of low perfusion area in the treatment group were significantly lower than that in the control group, with statistical significance(P < 0.05). After treatment, the serum levels of ACA, CXCL12, and MMP-8 in two groups were significantly decreased(P < 0.05), and the serum levels of ACA, CXCL12, and MMP-8 in the treatment group were lower than those in the control group(P < 0.05). Conclusion Naoan Capsules combined with Idebenone Tablets has

关 键 词：脑安胶囊 艾地苯醌片 急性脑梗死 FCA评分 NIHSS评分 低灌注区面积 抗心磷脂抗体 趋化因子配体12 基质金属蛋白酶8 

分 类 号：R971[医药卫生—药品]